Crelosidenib
![]() | |
| Clinical data | |
|---|---|
| Other names | LY3410738 |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| ChemSpider | |
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C28H36N6O3 |
| Molar mass | 504.635 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Crelosidenib is an investigational new drug that is being evaluated for the treatment of cancer. It acts as a selective inhibitor of isocitrate dehydrogenase 1 (IDH1), an enzyme that plays a crucial role in cellular metabolism and is frequently mutated in various cancers, including cholangiocarcinoma.[1][2]
References
- ↑ Zarei M, Hue JJ, Hajihassani O, Graor HJ, Katayama ES, Loftus AW, et al. (February 2022). "Clinical development of IDH1 inhibitors for cancer therapy". Cancer Treatment Reviews. 103 102334. doi:10.1016/j.ctrv.2021.102334. PMID 34974243.
- ↑ Demir T, Moloney C, Mahalingam D (July 2024). "Emerging targeted therapies and strategies to overcome resistance in biliary tract cancers". Critical Reviews in Oncology/Hematology. 199 104388. doi:10.1016/j.critrevonc.2024.104388. PMID 38754771.
